Randomised comparison of a balloon-expandable and self-expandable valve with quantitative assessment of aortic regurgitation using magnetic resonance imaging
Open Access
- 1 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Netherlands Heart Journal
- Vol. 28 (5), 253-265
- https://doi.org/10.1007/s12471-020-01414-0
Abstract
Introduction Transcatheter aortic valve implantation (TAVI) is a safe and effective treatment for inoperable, intermediate- or high-risk patients with severe symptomatic aortic stenosis and has been associated with excellent clinical outcomes. A clinically relevant remaining problem is aortic regurgitation (AR) post-TAVI, which is associated with increased mortality. Therefore, we conducted a prospective randomised trial to assess the safety and efficacy of a first-generation self-expandable valve (SEV; CoreValve) and a third-generation balloon-expandable valve (BEV; Sapien 3) with respect to clinical outcomes and AR as determined quantitatively by magnetic resonance imaging (MRI). Methods The ELECT study was an investigator-initiated, single-centre trial involving patients with severe symptomatic aortic stenosis and with a clinical indication for transfemoral TAVI. Fifty-six patients were randomly assigned to the BEV or SEV group. Results AR determined quantitatively by MRI was lower in the BEV than in the SEV group [regurgitant fraction: 1.1% (0-8.0) vs 8.7% (3.0-14.8) for SEV; p & x202f;= 0.01]. Secondary endpoints according to the criteria of the Second Valve Academic Research Consortium (VARC-2) showed BEV to have better early safety [0 (0%) vs 8 (30%); p & x202f;= 0.002] at 30 days and a lower risk of stroke [0 (0%) vs 5 (21%); p & x202f;= 0.01], major adverse cardiac and cerebrovascular events [0 (0%) vs 10 (38%); p & x202f;< 0.001] or death [0 (0%) vs 5 (19%); p & x202f;= 0.02] in the 1st year compared with SEV. Conclusions The use of the latest generation of BEV was associated with less AR as quantitatively assessed by MRI. Although the use of MRI to quantify AR is not feasible in daily clinical practice, it should be considered as a surrogate endpoint for clinical outcomes in comparative studies of valves for TAVI. ClinicalTrials.gov number NCT01982032.Keywords
This publication has 31 references indexed in Scilit:
- Postprocedural Aortic Regurgitation in Balloon-Expandable and Self-Expandable Transcatheter Aortic Valve Replacement ProceduresCirculation, 2014
- Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE StudyEuropean Heart Journal, 2014
- Power failure: why small sample size undermines the reliability of neuroscienceNature Reviews Neuroscience, 2013
- Incidence, Predictors, and Outcomes of Aortic Regurgitation After Transcatheter Aortic Valve ReplacementJournal of the American College of Cardiology, 2013
- Paravalvular Leak After Transcatheter Aortic Valve ReplacementJournal of the American College of Cardiology, 2013
- Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve ImplantationJournal of the American College of Cardiology, 2012
- Registry of Transcatheter Aortic-Valve Implantation in High-Risk PatientsNew England Journal of Medicine, 2012
- Long-Term Outcomes After Transcatheter Aortic Valve Implantation in High-Risk Patients With Severe Aortic Stenosis: The U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) RegistryJournal of the American College of Cardiology, 2011
- Comparison of Severity of Aortic Regurgitation by Cardiovascular Magnetic Resonance Versus Transthoracic EchocardiographyThe American Journal of Cardiology, 2011
- Severity of aortic regurgitation: interstudy reproducibility of measurements with velocity-encoded cine MR imaging.Radiology, 1992